Quantum Natural Family Planning Pilot

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-29

Study Completion Date

2021-04-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

•The Pilot study will involve current Marquette Method users who own and use a ClearBlue Fertility monitor and who will be asked to simultaneously use the Mira monitor for the sake of comparing the two devices to monitor the menstrual cycle.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Quantum Menstrual Health Monitoring Study

NCT05936840

Menstrual Cycle Abnormal Polycystic Ovary Syndrome Athletes

RECRUITING

Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.

NCT01480778

Irregular Periods

COMPLETED PHASE3

Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant

NCT04074174

Overweight Obesity

COMPLETED PHASE1

A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant

NCT06461039

Obesity

COMPLETED PHASE1

Study of Safety and Efficacy of an Oral Contraceptive

NCT00391807

Contraception

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* The Mira fertility monitoring system (www.miracare.com) is a new home-use hormone tracking device with the ability to quantitatively measure reproductive hormones in the urine but is also synced to a smart phone App that provides a graphic representation of the hormonal levels throughout a menstrual cycle.
* The Mira monitor will be compared to the ClearBlue Fertility Monitor for its ease of use, satisfaction, and accuracy.
* The Mira hormonal monitor and App system has not been tested for its use in Natural Family Planning (NFP).
* The Pilot study will involve current Marquette Method users who own and use a ClearBlue Fertility monitor and who will be asked to simultaneously use the Mira monitor for the sake of comparing the two devices.
* Female participants invited to participate will need to meet the following criteria:
* Age 18 to 42 years
* Menstrual cycle ranging between 21-42 days
* At least 3 cycles after cessation of breastfeeding
* Not currently on medications that affect ovulation and 3 months prior
* Not currently pregnant or breastfeeding
* No known fertility problems
* Not planning on achieving pregnancy during the 3 menstrual cycles of the study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fertility Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Prospective cohort analysis of three menstrual cycles of hormone data, comparing two fertility monitors that analyze urine hormones. Satisfaction and ease of use will be assessed using surveys. Individual data will be anonymized.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Anonymized demographic data

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single cohort

All 20 participants will use ClearBlue and Mira monitors on first morning urine

Group Type EXPERIMENTAL

Mira monitor comparison to ClearBlue monitor

Intervention Type DEVICE

Testing first morning urine with hormone test sticks at home

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mira monitor comparison to ClearBlue monitor

Testing first morning urine with hormone test sticks at home

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Menstrual cycle ranging between 21-42 days

* At least 3 cycles after cessation of breastfeeding

Exclusion Criteria

* • Not currently on medications that affect ovulation and 3 months prior

* Not currently pregnant or breastfeeding
* No known fertility problems
* Not planning on achieving pregnancy during the 3 menstrual cycles of the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

42 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes